Podcasts about synthego

Recently, I've enjoyed interviewing people I have never spoken to before. Harrison Waid, the co-founder of Succession, is one of those. Shout out to Teddy Lin for connecting us. I took this as an opportunity to learn about Harrison and his business as well as a personal challenge to interview someone “cold”. OK, I did some research, so maybe “room temperature”.First of course, I needed him to explain Succession, co-founded with Nick Clare (who I hope to have on another time). They noticed life science companies struggling to translate great technology into successful market entry and sales growth. Succession was founded to address this, offering specialized services exclusively for life science sales teams – everything from lead generation and sales training to recruitment and optimizing internal systems like CRMs with automation and AI. Harrison called it a "vertical service company" for life science sales.The idea for it wasn't a sudden flash of insight but more of a "slow burn." While at Synthego and after moving to the UK, he initially thought about general consulting. He quickly found that clients wanted concrete outcomes, not just advice. The real traction came when they packaged their expertise into specific, deliverable-focused services – that's when things really took off.I'm always interested in people who come from other backgrounds outside of life science. He made his start was in software sales. A friend brought him into Synthego, a CRISPR company, initially for consulting. At that point, his knowledge of biology was that "the mitochondria is the powerhouse of the cell." But he was excited by the potential of the technology. He immersed himself in learning the science and business of biotech, leveraging online resources and learning from his colleagues. Once again, curiosity = superpower! Asking "dumb questions" is an underrated skill. Those outside perspectives can challenge assumptions and benefit both the business and the individual willing to learn.I'd prepped some questions, but the morning of our interview, I stumbled upon a recent LinkedIn post Harrison made contrasting "old" and "new" ways in biotech sales. I saw some insightful comments from people we both respect, like Owen Swift. I knew this would be worth digging into.Harrison framed the "new way" around leveraging technology to move beyond inefficient models like (old way) simply scaling headcount. I picked a few points from his post for discussion:Small, High-Output Teams + RevOps/Content/Automation: He explained how technology now allows high-performing reps to be supported by robust systems (managed by Revenue Operations) that automate much of the prospecting and research previously done by separate inside sales roles. This frees up skilled sellers to focus on closing.AI for Intent & Sequencing: We discussed how AI can go beyond basic alerts to analyze market signals, identify key opportunities, score leads, and even assist with outreach, providing reps with powerful, timely intelligence.Content & Personal Brand for Demand Gen: I strongly agree with this one. There is a compelling case for reps building their personal brands on platforms like LinkedIn. He argued, quite correctly in my view, that authentic content from individuals resonates far more than corporate posts and that companies restricting this are missing a huge opportunity.Video Outreach: I shared my own recent positive experience with video messaging, having secured a meeting from one just last week. Harrison pointed out how video cuts through the noise, humanizes interactions, and is effective for both prospecting and follow-ups. We agreed authenticity is more important than perfection.The Best Reps Get the Best Opportunities: This one may be controversial, as it goes against the idea of pure "fairness" in lead distribution. He would argue that for maximizing company revenue, it makes sense to give the highest potential leads to the reps most likely to convert them. He acknowledged territory assignments are inherently unfair anyway and suggested lower performers could develop on less critical leads. This leads to discussions about efficiency, long-term strategy, and even healthy team turnover.Compensation plans inevitably drive behavior and can always be gamed, so no system is perfect. It comes down to your goal and again, long-term strategy. As someone who hasn't formally been in sales, I can see the attraction to developing skills on low risk opportunities.If these ideas got you thinking, you might check out the SalesDNA Podcast, Hosted by Harrison and Nick. These cold conversations have been a blast and educational for me beyond the content. I have more lined up. If you aren't subscribed, now might be a good time…Your deepest insights are your best branding. I'd love to help you share them. Chat with me about custom content for your life science brand. Or visit my website.BTW, I hope you'll consider joining me here: This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit cclifescience.substack.com

In this episode, Matt sits down with Aditya Vempaty, VP of Marketing at MoEngage, to talk about a topic every marketing leader has wrestled with: reporting on the right metrics. Aditya has led marketing at companies like Nutanix, Amplitude, and Synthego - and he's learned how to build dashboards and reporting frameworks that actually communicate marketing's impact across leadership, sales, and finance.Matt and Aditya cover:Why marketing metrics should translate performance into a common language the business understandsThe four buckets of metrics every B2B team should trackHow often you should be reporting on metricsThe exact 7 metrics Aditya uses to report up, down, and across the orgTimestamps(00:00) - – Intro to Aditya (03:45) - – Why communicating marketing's impact is a challenge for many teams (06:21) - – The importance of using a common language when reporting to leadership (08:59) - – Breaking marketing metrics into four key buckets (12:14) - – How pipeline coverage connects marketing to revenue (14:43) - – Reporting on efficiency: CAC, cost per opportunity, and more (17:58) - – The role of awareness metrics and how to contextualize them (21:55) - – How marketing and sales alignment can be measured effectively (24:24) - – The 7 core marketing metrics Aditya reports on regularly (28:07) - – How often should marketing be reporting metrics? (30:51) - – Dashboards, recurring meetings, and what execs actually care about (33:43) - – Advice for first-time marketing leaders on building reporting habits (35:57) - – Why clarity beats complexity when it comes to data (38:39) - – Final thoughts Send guest pitches and ideas to hi@exitfive.comJoin the Exit Five Newsletter here: https://www.exitfive.com/newsletterCheck out the Exit Five job board: https://jobs.exitfive.com/Become an Exit Five member: https://community.exitfive.com/checkout/exit-five-membership***Today's episode is brought to you by Grammarly.Ever have one of those weeks where you spent more time replying to Slack and email than doing actual marketing work?You're not alone. The average marketing team spends 28+ hours a week just keeping up with comms.That leads to burnout, frustration, and a whole lot of performative productivity that doesn't actually move the needle.AI-fluent marketing teams are changing that. Grammarly's 2025 Productivity Shift Report shows how they're using AI to:– Cut down on back-and-forth– Automate content, research, and reporting– Eliminate busywork– Make space for strategyWe're marketers because we love crafting campaigns, driving revenue, and proving impact – not spending all day buried in messages.Get the report and see how top teams are making AI actually useful.Visit go.grammarly.com/exitfive to grab it.***Thanks to my friends at hatch.fm for producing this episode and handling all of the Exit Five podcast production.They give you unlimited podcast editing and strategy for your B2B podcast.Get unlimited podcast editing and on-demand strategy for one low monthly cost. Just upload your episode, and they take care of the rest.Visit hatch.fm to learn more

Agilent Technologies, Inc. v. Synthego Corp.

Jon Hartley and Joe Lonsdale discuss Joe's career, co-founding Palantir, Addepar, and OpenGov, venture capital investing, defense tech, DOGE, Elon Musk, regulation, and the prospects for generative artificial intelligence. Recorded on December 12, 2024. ABOUT THE SPEAKERS: Joe Lonsdale is the founder and managing Partner at 8VC, an early-stage venture capital firm managing over $6 billion in capital. In 2003, he founded Palantir Technologies (NYSE:PLTR), a global software company known for its work supporting US and its allies' defense and intelligence. Since then, he has founded more than a dozen prominent companies, including Addepar, a wealth management platform with about $5 trillion, and OpenGov, the leading cloud software provider for local governments. He continues to create and scale companies through the 8VC Build program.  As an investor, Joe was an early backer of companies like Anduril Industries, Oculus (acq.FB), Guardant Health (NASDAQ:GH), Oscar (NYSE:OSCR), Illumio, Wish (NASDAQ:WISH), JoyTunes, Blend (NYSE:BLND), Flexport, Joby Aviation (NYSE:JOBY), Orca Bio, Qualia, Synthego, RelateIQ (acq. CRM), Yugabyte, and others.  Joe and his wife Tayler are active in a variety of philanthropic and institutional pursuits. In 2018, they founded the non-partisan Cicero Institute, which crafts and advances policies to promote effective and accountable governance, and is now successfully battling special interests with teams in over a dozen states. In 2021, Joe became the founding chairman of the board of the University of Austin(UATX), a new university dedicated to restoring the pursuit of truth in higher education. He also sits on the board of the Ronald Reagan Presidential Foundation & Institute. ​  Joe, Tayler, and their four daughters live in Austin, TX. Jon Hartley is the host of the Capitalism and Freedom in the 21st Century Podcast at the Hoover Institution and an economics PhD Candidate at Stanford University, where he specializes in finance, labor economics, and macroeconomics. He is also currently an Affiliated Scholar at the Mercatus Center, a Senior Fellow at the Foundation for Research on Equal Opportunity (FREOPP), and a Senior Fellow at the Macdonald-Laurier Institute. Jon is also a member of the Canadian Group of Economists, and serves as chair of the Economic Club of Miami. Jon has previously worked at Goldman Sachs Asset Management as well as in various policy roles at the World Bank, IMF, Committee on Capital Markets Regulation, US Congress Joint Economic Committee, the Federal Reserve Bank of New York, the Federal Reserve Bank of Chicago, and the Bank of Canada.  Jon has also been a regular economics contributor for National Review Online, Forbes, and The Huffington Post and has contributed to The Wall Street Journal, The New York Times, USA Today, Globe and Mail, National Post, and Toronto Star among other outlets. Jon has also appeared on CNBC, Fox Business, Fox News, Bloomberg, and NBC, and was named to the 2017 Forbes 30 Under 30 Law & Policy list, the 2017 Wharton 40 Under 40 list, and was previously a World Economic Forum Global Shaper. ABOUT THE SERIES: Each episode of Capitalism and Freedom in the 21st Century, a video podcast series and the official podcast of the Hoover Economic Policy Working Group, focuses on getting into the weeds of economics, finance, and public policy on important current topics through one-on-one interviews. Host Jon Hartley asks guests about their main ideas and contributions to academic research and policy. The podcast is titled after Milton Friedman‘s famous 1962 bestselling book Capitalism and Freedom, which after 60 years, remains prescient from its focus on various topics which are now at the forefront of economic debates, such as monetary policy and inflation, fiscal policy, occupational licensing, education vouchers, income share agreements, the distribution of income, and negative income taxes, among many other topics. For more information, visit: capitalismandfreedom.substack.com/

There are countless reasons to admire Mark Hamalainen, and one of them is his brutal honesty. While many longevity influencers confidently declare that longevity escape velocity and indefinite lifespans are just around the corner, you won't get such easy assurances from Mark.That's because, and this might seem counterintuitive at first, he's one of the most deeply committed advocates for solving aging that I've encountered. Mark, a former director of science at Synthego and a former researcher at SENS Research Foundation (Aubrey de Grey has called him his protégé), has dedicated over two decades to tackling humanity's greatest challenge.You see, Mark's honesty doesn't stem from pessimism, but from a deep commitment to reality-based thinking. His mission isn't driven by hype but by a relentless pursuit of tangible progress in the fight against aging.I (Peter) first met Mark at the Longevity Biotech Fellowship (LBF) retreat in Sweden in January 2024, where I had the opportunity to witness his vision and dedication firsthand. It left a lasting impression, not only on me but likely on everyone who attended. Here was someone who wasn't just dreaming about a future where aging is solved - he was meticulously planning it, working hard to remove the roadblocks that stand in the way.His work with the LBF, the Longevity Acceleration Roadmap, and his broader efforts in the longevity community are all about taking concrete, actionable steps toward a future where the passing of time is not a death sentence - all the while knowing that this goal is one of the most complex challenges humanity has ever faced.In this episode, Mark discusses several key strategies that he believes are essential to making real progress. These include advancing bioengineering to gain precise control over biological processes, developing comprehensive data sets to better understand aging at a molecular level, and exploring visionary ideas like the replacement strategy. He also highlights the potential of biostasis and cryopreservation as a last resort, potentially offering a way to preserve life until future technologies can fully reverse aging.So, while Mark may not offer the easy assurances that some in the longevity space do, he offers something far more valuable: a realistic and deeply informed plan of action, a commitment to truth over convenience, and above all, a profound hope that by facing the realities of aging head-on, we can one day overcome them. Hosted on Acast. See acast.com/privacy for more information.

Top takeaways: - He shares his ACB framework- How you need to think about brand- Effective ways to up-level your sales team- How goals get passed down from the board to your quotaWatch this episode on Youtubehttps://www.youtube.com/playlist?list=PLNpnig-8yQuwbM5AueF_cDRub_GQW5FB2About: - Ted Tisch- https://www.linkedin.com/in/theodoretisch/- GM at BioRad and COO at Synthego and MammothDownload the life science sales rep toolkit: https://www.succession.bio/content/life-science-sales-toolkitAbout Succession: A life science sales training and community platform led by the top sales experts in the industry.- Get instant access to hours of on-demand and live training content.- Access to 100s of resources and tools- Network and learn from other growth-minded life science sales repsJoin Succession: https://www.succession.bio/join

Mark Hamalainen is cofounder of the Longevity Biotech Fellowship. His career has progressed from manual bench work in academia, to lab automation at Synthego, to longevity movement building - always seeking better methods and higher leverage ways to accelerate progress.He shares an actionable roadmap for an unlimited healthy lifespan, divided into four promising areas for progress. He shares updates and information regarding The Longevity Biotech Fellowship, whose mission is to enable a future where everyone can access a healthy, unlimited lifespan. Dive deeper into the session: Full SummaryAbout Foresight InstituteForesight Institute is a research organization and non-profit that supports the beneficial development of high-impact technologies. Since our founding in 1987 on a vision of guiding powerful technologies, we have continued to evolve into a many-armed organization that focuses on several fields of science and technology that are too ambitious for legacy institutions to support.Allison DuettmannThe President and CEO of Foresight Institute, Allison Duettmann directs the Intelligent Cooperation, Molecular Machines, Biotech & Health Extension, Neurotech, and Space Programs, alongside Fellowships, Prizes, and Tech Trees. She has also been pivotal in co-initiating the Longevity Prize, pioneering initiatives like Existentialhope.com, and contributing to notable works like "Superintelligence: Coordination & Strategy" and "Gaming the Future".Get Involved with Foresight:Apply: Virtual Salons & in-person WorkshopsDonate: Support Our Work – If you enjoy what we do, please consider this, as we are entirely funded by your donations!Follow Us: Twitter | Facebook | LinkedInNote: Explore every word spoken on this podcast through Fathom.fm, an innovative podcast search engine. Hosted on Acast. See acast.com/privacy for more information.

Since it's discovery, CRISPR Cas9 gene editing technology has blossomed and boomed.  It's moved from a highly technical niche technique to one that is arguably mainstream and being applied to countless challenges in applied biology. In this episode we talk with Travis Hardcastle, who previously worked in R&D to develop gene editing products and is now a Product Manager for Engineered Cell Lines at Synthego. Travis helps explain the basics of gene editing and how it's being applied to cell line engineering and provides a well-informed perspective on the past, present, and future of the CRISPR revolution. This conversation touches on automation, bioproduction, and the feedback loop of guide DNA and cell line development. The therapeutic application of this technology, which has the potential to truly enable personalized medicine, is a focal point of this personal and informative conversation.  Tune in today. Subscribe to get future episodes. Share with a friend or colleague that might enjoy too! Visit thermofisher.com/molbioschool to access molecular biology resources and educational content. Experience the Speaking of Mol Bio podcast in its extended video format for a more immersive journey, while also ensuring accessibility with downloadable transcripts for each episode.Watch now at thermofisher.com/podcast-video

Thursday, March 3, 2022 Hoover Institution, Stanford University   The Hoover Institution Technology, Economics, and Governance Working Group invites you to a virtual discussion on Antitrust & the Future of Big Tech on Thursday, March 3, 2022 from 9:00 am - 10:00 am Pacific. It's no secret that the Biden administration and 117th Congress are targeting Big Tech. Lawmakers from both sides of the aisle are pursuing legislation that targets the market power amassed by companies including Amazon, Apple, Facebook, and Google. Leaders at the Federal Trade Commission (FTC) and the Department of Justice's Antitrust Division–key enforcement agencies–are also aligned against Big Tech; the FTC is actively prosecuting a lawsuit against Facebook for monopoly behavior.  Joe Lonsdale, Managing Partner at 8VC and Co-Founder of Palantir, joins us virtually to discuss how antitrust law may impact high-tech firms' size and sway. He recently proposed in a February 7, 2022 Wall Street Journal article that Amazon should be split into two businesses – AWS and Amazon.com – not because big is “bad,” but because Amazon's ability to undercut its competitors with below-cost prices may stifle the scope and speed of innovation in areas like logistics. We hope you will join us to learn more about what antitrust advocates are getting right, what they are getting wrong, and the potential impact of breaking up Big Tech. ABOUT THE SPEAKER Joe Lonsdale is a technology entrepreneur and investor. He is the managing partner at 8VC, a US-based venture capital firm that manages several billion dollars in committed capital. He was an early institutional investor in many notable technology start-ups including Oculus (acq.FB), Guardant Health (NASDAQ: GH), Oscar (NYSE: OSCR), Illumio, Anduril, Wish (NASDAQ: WISH), JoyTunes, Blend (NASDAQ: BLND), Flexport, Joby Aviation (NASDAQ: JOBY), Cityblock, Orca Bio, Qualia, Synthego, RelateIQ (acq.CRM), and many others. Joe has been on the Forbes 100 Midas List since 2016 and was the youngest member included in 2016 and 2017, and ranked 18th in the world last year. Before focusing on institutional investing, Joe co-founded Palantir (NASDAQ: PLTR) a global software company known for its work in defense and other industries, as well as for providing the platform to run the COVID-19 common operating picture for key decision makers in over 35 countries. After Palantir, he founded and remains as Chairman of both Addepar, which has over $3 trillion USD managed on its wealth management technology platform, and OpenGov, which provides software for over 2,000 municipalities and state agencies. More recently, he is also a co-founder of Affinity, Epirus, Resilience Bio, and other mission-driven technology companies, which he continues to create with his team out of the 8VC Build program. Joe began his career as an early executive at Clarium Capital, which he helped grow into a large global macro hedge fund. He also worked with PayPal while he attended Stanford. PARTICIPANTS Bradley Body, Mark Brilliant, Tom Gilligan, Taylor McLamb, Max Meyer, Elena Pastorino, Meghana Reddy, Manny Rincon-Cruz, Marie-Christine Slakey, John Taylor, Amy Zegart  

Hear from Dr. Neville Sanjana about his publication detailing the use of modified guide RNAs and protein delivery to enhance control of CRISPR/Cas13 activity.

In this episode, Joe Lonsdale gives actionable advice on multiple topics such as how to organize your day, what to focus on when thinking about career success and how to stay motivated. Joe founded Palantir, a $44B public company, and was an early institutional investor in notable companies including Wish, Oculus, Oscar Health, Synthego & Guardant Health. In 2017 he was the youngest member of the Forbes 100 Midas List. He studied at Stanford and has a BS in Computer Science. He is the founder of 8VC a venture capital firm that invested in us and where I'm an advisor as well. Altogether, these funds manage over $3.5 billion in capital. Chapters 00:00 Intro 01:05 What are your daily routines? 05:35 What health and fitness rules do you follow 08:05 What do you see in the near future for health optimization? 12:35 How do you optimize your productivity? 15:05 What should people focus on when thinking about success? 17:35 How do you maintain your motivation and work ethic? 20:45 How do you stay happy and maintain a good mentality about life? 22:15 Why should good leaders learn how to do? 25:35 What advice would you give your younger self? 27:55 Is there a failure that you learned a lot from? 31:05 How do you deal with difficulties at work while managing others? 33:35 What is your take on modern masculinity? 38:35 What virtues should every man focus on? 41:55 How should a man go about bettering himself? 44:45 Outro

8VC is a Silicon-Valley based technology investment firm investing in visionary teams and backing industry-transforming companies, currently managing $3.5bn in AUM. About one third of their current fund is dedicated towards the BioIT space. 8VC’s portfolio represents a large early crop of now next gen biotech unicorns including but not limited to Orca Bio, Synthego, Resilience, and Lyell Immunopharma which have generated playbooks for others startups to follow. Francisco Giminez and David Moskowitz are two integral members of the 8VC team which developed the Bio-IT investment thesis. Francisco is a Partner at 8VC focusing on Bio-IT investments and Enterprise AI. He received a PhD from Stanford in Biomedical Informatics. During this time, he also worked as a Resident Data Scientist at Formation8 Partners where he helped startups to strategize, prototype, and recruit for data products. He also is the founder of Catenus Science, a data science consulting and recruiting firm that used an apprenticeship model to help early stage companies build data science teams. David is a Principal at 8VC who also received his PhD at Stanford as part of the Biomedical Informatics Program. At Stanford, his work was focused on applying statistical and machine learning approaches to regulatory genomics, epigenetics, and pipeline development for analysis of high throughput sequencing data. Prior to his time at Stanford, David was a Bioinformatic Analyst at Einstein College of Medicine where he worked on the genetics of aging and human disease.

In This Episode, Dr. Cam interviews the millionaire entrepreneur and investor Joe Lonsdale. Joe founded Palantir, a $44B public company, and was an early institutional investor in notable companies including Wish, Oculus, Oscar Health, Synthego & Guardant Health. In 2017 he was the youngest member of the Forbes 100 Midas List. He studied at Stanford and has a BS in Computer Science. He is the founder of 8VC a venture capital firm that invested in us and where I'm an advisor as well. Altogether, these funds manage over $3.5 billion in capital.

Joe Lonsdalewas an early institutional investor in notable companies including Wish, Oculus, Oscar, Illumio, Blend, Orca Bio, RelateIQ, Joby Aviation, Synthego, Guardant Health, and in 2016 and 2017 was the youngest member of the Forbes 100 Midas List. He is also the co-founder of Palantir, a multi-billion dollar global software company best known for its work in defense and finance. Most recently, he was a founding partner at Formation 8, one of the top-performing private funds and the precursor to 8VC. Dakin Sloss is an entrepreneur, investor, and philanthropist. He is the Founder and General Partner of Prime Movers Lab, the world's leading partner of breakthrough scientific startups. He has led investments in and is a Board Member at Momentus, Heliogen, Covaxx, Tarana, and Carbon Capture. Prime Movers Lab I is on track to be one of the top-performing funds of 2018. Prior to founding Prime Movers Lab, Dakin served as founding CEO of Tachyus and OpenGov. ————————————————————————— To learn more about this episode, including podcast transcripts and show notes, visit *salt.org/talks* ( http://salt.org/talks ) Moderated by Anthony Scaramucci.

In this episode, Paul Dabrowski, CEO of Synthego, and Robert Deans, CSO of Synthego discuss the CRISPR silver linings of 2020 and predict a strong upcoming year for gene editing in 2021. 

----------------- *Podcast outline* ----------------- [01:35] Aditya’s background [03:20] What consumers care about more than your product [05:35] Why companies need to identify the problems prospective customers are trying to solve [08:45] Why retention is more important than acquisition [10:48] The biggest lesson Aditya has learned in his career [12:00] How Aditya builds trust with consumers through “problem marketing” [13:35] Why building community is important and how Aditya builds community [14:24] What it was like for Aditya to go from a SaaS product to biotechnology [16:31] How Youtube will be leveraged more in a B2B perspective ----------------------- *Aditya’s Inspirations* ----------------------- Tiffany To ( https://www.linkedin.com/in/tiffto ) Brian Balfour ( https://www.linkedin.com/in/bbalfour ) --------------------- *Connect with Aditya* --------------------- Linkedin ( https://www.linkedin.com/in/adityavempaty ) Twitter ( https://twitter.com/avemii )

During this episode of Tech Qualified, Tristan Pelligrino chats with Aditya Vempaty, the VP of Marketing at Synthego. Aditya chats about his past working experience prior to Synthego and highlights how it’s important to build trust with prospects with B2B marketing. Aditya also covers why he enjoys the startup culture so much and pinpoints what drives him as a marketer. Episode  Highlights Aditya’s education included an electrical engineering degree from Georgia Tech and he started his professional career as a programmer before moving into a marketing role. Aditya discusses his inclination towards startup environments and highlights why he’s attracted to these types of companies.  During the interview, Aditya provides some context to what Synthego does - it’s a genome engineering company and develops products for scientists & researchers.  The organization’s ideal customer profile is someone who understands the power of CRISPR and can utilize full stack genome editing. When coming on board, Aditya focused on purely understanding customers through conversations with researchers. Aditya had conversations with over one hundred customers in his first quarter. Aditya utilized conversations from the Synthego inside sales team as a way to develop an understanding of the company’s customer base. When arriving at Synthego, the team had content in place and had marketing running...but he then shifted the focus to educating the customer. Aditya developed a process for creating content around CRISPR and its uses - not just from blog posts, but also guides that talked about how to get started with CRISPR and how to get started with genome engineering. One of the big pillar pieces of content that’s worked quite well for Synthego is their industry report - a process that includes data from surveys (from customers, non-customers and industry leaders). Developing educational content for customers (as well as creating SEO value) is not a short-term game...it’s a long-term strategy that does take time - so it’s important to set expectations with the company up front. For short-term leads, Synthego focused on events and that helped balance some of their long-term strategies around content. He explained the difference between scaling a business versus growing a business. Long-term marketing initiatives can be less expensive overall, but they take a lot of time to build. On the other hand, short-term investments which drive leads can be more expensive. Aditya breaks down some of the key metrics the team monitors on the marketing team and stresses the importance of always keeping an eye on revenue as well. Synthego works hard on delivering valuable content for the end-user. He pointed out the importance of storytelling for technology companies. Key Points Aditya discussed one challenge “One thing I've found is that regardless of industry, there's a problem that the customer is always trying to solve, and oftentimes products don't address the problem. They address how they can solve it for them. Instead of trying to understand what the problem actually is.” There is a difference between scaling a business versus growing a business.  One can grow a business through events, Google Ads, LinkedIn purchases, but to scale it, you have to invest in long-term strategies that deliver value to the end-user. Resources Aditya Vempaty: LinkedIn Aditya Vempaty: Twitter Synthego: Website The Startup Chat with Setli and Hiten: Website Motion: Ultimate Thought Leadership Course for B2B Tech Companies

In this interview, Paul Dabrowski, CEO of Synthego, talks about how Synthego got started, his mantra behind leading the company, and future directions. He also offers insights into Synthego’s unique capabilities⁠—the powerful combination of engineering and biology that enable scaling.

In this episode of Talk Nerdy, Cara is joined by the Head of Science at Synthego, Dr. Kevin Holden. They talk about new advances in genetic engineering technology, such as the CRISPR-CasX system. Also discussed: what the future holds for synthetic biology and related fields. Follow Kevin’s work: @Synthego.

In this episode of Talk Nerdy, Cara is joined by the Head of Science at Synthego, Dr. Kevin Holden. They talk about new advances in genetic engineering technology, such as the CRISPR-CasX system. Also discussed: what the future holds for synthetic biology and related fields. Follow Kevin’s work: @Synthego.

What if you could plant a seed, and grow a building? A few episodes ago we talked to Paul Dabrowski, CEO of Synthego, a company building tools that help biologists. Paul's hope for the field of synthetic biology is a path to curing all disease. But in a world of further biological understanding, there are few limits to what we can grow. Let’s talk about the biological factory.

Learn about 4 up-and-coming batteries that could overtake lithium-ion; how microsleep happens without you even knowing it; and what you’re getting wrong about CRISPR gene editing technology, and how to get smart about it — with a little help from Minu Prabhune of Synthego. In this podcast, Cody Gough and Ashley Hamer discuss the following stories from Curiosity.com — with some help from Synthego’s Meenakshi Prabhune and Kevin Bryant — to help you get smarter and learn something new in just a few minutes: 4 Up-and-Coming Batteries That Could Overtake Lithium-Ion — https://curiosity.im/2sAwbdX Microsleep Happens Without You Even Knowing It — https://curiosity.im/2sv7ZK6 More from Synthego: CRISPR Cuts, Synthego’s official podcast — https://www.synthego.com/podcast “The Bench” Synthego Blog — https://www.synthego.com/blog About Synthego — https://www.synthego.com/company Follow Synthego on Twitter — https://twitter.com/synthego Meenakshi Prabhune on Twitter — https://twitter.com/minu_pr If you love our show and you're interested in hearing full-length interviews, then please consider supporting us on Patreon. You'll get exclusive episodes and access to our archives as soon as you become a Patron! https://www.patreon.com/curiositydotcom Download the FREE 5-star Curiosity app for Android and iOS at https://curiosity.im/podcast-app. And Amazon smart speaker users: you can listen to our podcast as part of your Amazon Alexa Flash Briefing — just click “enable” here: https://curiosity.im/podcast-flash-briefing.

Learn about CRISPR technology and applications in GMOs; a hallucinogenic plant that’s both beautiful and deadly; and how scientists are working together to understand Fast Radio Bursts, which are one of the universe’s greatest mysteries. In this podcast, Cody Gough and Ashley Hamer discuss the following stories from Curiosity.com — with some help from Synthego’s Meenakshi Prabhune and Kevin Bryant — to help you get smarter and learn something new in just a few minutes: The Hallucinogenic Angel's Trumpet Plant Is Beautiful and Deadly — https://curiosity.im/2EbynRj How scientists are working together to solve one of the universe's mysteries — https://curiosity.im/2EfVhG2 More from Synthego: CRISPR Cuts, Synthego’s official podcast — https://www.synthego.com/podcast About Synthego — https://www.synthego.com/company Follow Synthego on Twitter — https://twitter.com/synthego Meenakshi (Minu) Prabhune on Twitter — https://twitter.com/minu_pr If you love our show and you're interested in hearing full-length interviews, then please consider supporting us on Patreon. You'll get exclusive episodes and access to our archives as soon as you become a Patron! https://www.patreon.com/curiositydotcom Learn about these topics and more on Curiosity.com, and download our 5-star app for Android and iOS. Then, join the conversation on Facebook, Twitter, and Instagram. Plus: Amazon smart speaker users, enable our Alexa Flash Briefing to learn something new in just a few minutes every day!

Dr. Ania Wronski, Product Manager for the Engineered Cells portfolio at Synthego, discusses how their new engineered cells products are enabling CRISPR access to researchers worldwide. Learn about the different ways in which researchers use knockout cell pools & their advantages over RNAi.

Reed Kelso, Head of Cell Engineering Research and Applications at Synthego, is a bio-wizard. In this episode, Kevin & Minu catch up with Reed about his role at Synthego and the day-to-day operations at the fast paced start-up. Reed talks about the revolutionary engineered cells products that he and his team recently launched & the hard work behind this amazing achievement. He also speculates about the future applications of CRISPR; his bets are on CRISPR making a massive splash in agriculture!

Kevin Holden is the Head of Synthetic Biology at Synthego. Mr. Holden holds a PhD in Microbiology from University of California, Davis. He has over 10 years of experience in the biotechnology arena, with specific study and research in synthetic biology as well as in engineering, notably—metabolic pathways in microbes. Synthego's primary work is focused in software and synthetic RNA kits designed for CRISPR genome research and editing. Synthego uses AI and machine learning to assist researchers and developers with automation for genome engineering that provides for efficient research with consistent results, at a price point that allows for savings. With a strong background in engineering, Synthego's team applies engineering principles to synthetic biology practices, especially for gene editing. Holden's company, Synthego, works with hardware and software and utilizes advanced machine learning to assist in research platforms and technology, such as the CRISPR-Cas9 genome editing technology. CRISPR is the acronym for Clustered Regularly Interspaced Short Palindromic Repeats, which are the distinctive feature of a complete bacterial defense system and the foundation for CRISPR-Cas9 genome editing technology. Synthego's hardware platform allows for the synthesization of RNA, to guide CRISPR technology to a specific place on the genome in order to make an edit. Holden discusses how Synthego's automation allows scientists to skip steps traditionally needed for method development and thus focus their efforts more immediately on their actual research, as Synthego can provide gene edited cells directly to them. The synthetic biology expert explains some of the various areas that his company is currently focused on. In particular, Holden's team is very excited about the potential for their work to be of particular use to researchers working with monogenic, or single gene, diseases, including single gene mutations. Miraculously, cells can be extracted from a patient, edited, tested, and then ex vivo transplanted back into a patient to cure the disease. Edited, corrected cells, once implanted into the patient then grow new cells void of the mutation that was once causing the disease. Holden also provides a detailed analysis of their work in the amazing area known as CAR T-cell therapy. CAR T-cell therapy is the process in which a patient's immune system cells, or T cells, are edited so they will then begin to attack cancer cells upon reintroduction into the body. As the microbiology PhD explains, enabling scientists to obtain gene-edited cells for research will greatly facilitate, and accelerate, the complex study of disease and thus allow for new therapies to become available to the public sooner. Synthego's tech decreases time ordinarily spent on model building so scientists' efforts go directly into the research. And Holden explains how AI algorithms are best utilized within large data sets in order to train models.   But perhaps one of the most significant uses of this technology will be in the breeding of plants, to engineer them to produce more efficiently, become resistant to disease and even drought, and thus aid in providing needed food for the world. With so many uses for synthetic biology practices and gene editing, it's clear that engineering-based companies such as Synthego will be riding the wave of many coming breakthroughs in medicine and science for years to come.

David Jennions, a reformed physicist, shares his career shift and current role as the head of engineering for a leading biotech company, Synthego. Synthego is a corporation dedicated to making digital biology a reality by doing what he calls, “Building the factory behind the product.” In this episode we will get into mind blowing modern technology such as CRISPR, a tool used to make the molecules that are sent out for gene editing. To understand more about what this means, tune into this episode as we discuss behind the scenes of how the health industry has the potential to move away from general healthcare solutions, and move into more personalized treatment.

The CRISPR Journal Executive Editor Kevin Davis interviews Editor-In-Chief Rodolphe Barrangou. This episode of GUIDEpost is brought to you by Synthego, who's vision is to turn biology into an information science with the ultimate goal of dramatically extending the healthy human lifespan by providing genome engineering solutions. Learn more at www.synthego.com.

Paul Dabrowski is co-founder and CEO of Synthego, a company building a platform of tools for scientists. Paul discusses why CRISPR is much more precise than other gene editing techniques, how China has been pushing ethical boundaries, what it's like building a company with your brother, and how his time at SpaceX shaped the way he thinks.